146 related articles for article (PubMed ID: 31746435)
1. The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
Yamamura M; Sato Y; Takahashi K; Sasaki M; Harada K
Oncol Rep; 2020 Jan; 43(1):306-317. PubMed ID: 31746435
[TBL] [Abstract][Full Text] [Related]
2. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
3. Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.
Shi T; Gong J; Fujita K; Nishiyama N; Iwama H; Liu S; Nakahara M; Yoneyama H; Morishita A; Nonura T; Kobara H; Okano K; Suzuki Y; Masaki T
Int J Oncol; 2021 Feb; 58(2):199-210. PubMed ID: 33491760
[TBL] [Abstract][Full Text] [Related]
4. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1.
Duan X; Yang J; Jiang B; Duan W; Wei R; Zhang H; Mao X
Aging (Albany NY); 2021 Sep; 13(17):21325-21344. PubMed ID: 34499615
[TBL] [Abstract][Full Text] [Related]
7. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
8. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma.
Li S; Chai Y; Ding Y; Yuan T; Wu C; Huang C
Oncol Rep; 2019 Aug; 42(2):657-669. PubMed ID: 31173252
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin suppresses the migration of cholangiocarcinoma cells by down-regulating matrix metalloproteinase-9 expression via the AMPK-NF-κB signaling pathway.
Lee GR; Jang SH; Kim CJ; Kim AR; Yoon DJ; Park NH; Han IS
Clin Exp Metastasis; 2014 Dec; 31(8):897-907. PubMed ID: 25217963
[TBL] [Abstract][Full Text] [Related]
11. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
13. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
15. Five-(Tetradecyloxy)-2-furoic Acid Alleviates Cholangiocarcinoma Growth by Inhibition of Cell-cycle Progression and Induction of Apoptosis.
Boonnate P; Kariya R; Saranaruk P; Cha'on U; Sawanyawisuth K; Jitrapakdee S; Okada S; Vaeteewoottacharn K
Anticancer Res; 2021 Jul; 41(7):3389-3400. PubMed ID: 34230134
[TBL] [Abstract][Full Text] [Related]
16. Cratoxylum formosum Extracts Inhibit Growth and Metastasis of Cholangiocarcinoma Cells by Modulating the NF-κB and STAT3 Pathways.
Senggunprai L; Thammaniwit W; Kukongviriyapan V; Prawan A; Kaewseejan N; Siriamornpun S
Nutr Cancer; 2016; 68(2):328-41. PubMed ID: 26908056
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.
Zheng J; Li Q; Wang W; Wang Y; Fu X; Wang W; Fan L; Yan W
Oncol Rep; 2016 Feb; 35(2):809-16. PubMed ID: 26572808
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
19. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
Mol Carcinog; 2019 Jan; 58(1):19-30. PubMed ID: 30182496
[TBL] [Abstract][Full Text] [Related]
20. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
